MGF (Mechano Growth Factor)

MGF, or mechano growth factor, is a splice variant of the IGF-1 gene (also referred to as IGF-1Ec) that is naturally expressed in skeletal muscle in response to mechanical loading and micro-damage from exercise. Unlike systemic IGF-1, MGF is thought to act locally within the muscle where it is produced. As a synthetic research peptide, it is studied for its proposed role in activating dormant satellite cells that contribute to muscle fiber repair and growth. It is cleared from circulation very quickly, which shapes how it is typically administered in research settings. Reported benefits include proposed activation of satellite cells following mechanical muscle damage, suggested support for localized post-exercise muscle repair, interest as a targeted, acute-use recovery agent.

Reported ranges run 200-600 mcg. A low protocol is 200 mcg once daily on training days, and a high protocol is 600 mcg once daily on training days. This is reference information, not a dosing recommendation.

Estimated at a few minutes in unmodified form. That is what sets the dosing frequency, and it is why the timing guidance is after a workout.

Intramuscular: into muscle. Commonly injected directly into the trained muscle shortly after exercise due to its extremely short half-life.

3-4 weeks on, followed by 4-6 weeks off. Given its acute, localized action, use is typically framed around specific training blocks rather than continuous administration.

Reported side effects include very short half-life limits the window for any effect, injection site discomfort with intramuscular administration, unestablished long-term human safety profile, limited human trial data specific to synthetic mgf administration. Evidence level for this compound is emerging research.